Not provided
| ID | Type | Description | Link |
|---|---|---|---|
| CIV-22-05-039590 | Other Identifier | Eudamed |
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
The purpose of this prospective, pivotal, multi-center, single-arm, pre-market, investigational clinical study is to assess the safety and performance of Deternia™ Self-Gripping Resorbable Mesh when used for suture line reinforcement after midline laparotomy in clean and clean-contaminated fields (CDC Classification I and II). Data from this study will be used to support market applications and European post-market clinical follow-up needs (PMCF). The indication under investigation is reinforcement of midline laparotomy to limit the rate of incisional hernia (IH) in clean and clean-contaminated surgeries (CDC Classification I and II).
The primary objective of this investigation is to evaluate the performance of Deternia™ Self-Gripping Resorbable Mesh when used for suture line reinforcement after elective midline laparotomy in clean and clean-contaminated fields (CDC Classification I and II) at 12 months post-operatively and to demonstrate expected performance in terms of rate of IH occurrence relative to a performance goal (based on historical data on primary laparotomy incision suture closure with small bites only).
The secondary objectives are to evaluate the safety and performance of Deternia™ Self-Gripping Resorbable Mesh when used for suture line reinforcement after elective midline laparotomy in clean and clean contaminated fields (CDC Classification I and II) within 60 months postoperatively.
Not provided
Not provided
Not provided
Not provided
| Label | Type | Description | Intervention Names |
|---|---|---|---|
| Hernia prevention cohort | Experimental | single arm study, no control arm |
|
| Name | Type | Description | Arm Group Labels | Other Names |
|---|---|---|---|---|
| Self-Gripping Resorbable Mesh | Device | Self-Gripping Resorbable Mesh used for suture line reinforcement after midline laparotomy in clean and clean-contaminated fields (CDC Classification I and II). |
| Measure | Description | Time Frame |
|---|---|---|
| Incisional Hernia Rate | Occurrence of incisional hernia assessed by clinical examination and abdominal ultrasound exam | 12 months |
| Measure | Description | Time Frame |
|---|---|---|
| Incisional Hernia Rate | Occurrence of incisional hernia assessed by clinical examination and abdominal ultrasound exam | 24- and 36-months |
| Incisional Hernia Rate | Occurrence of incisional hernia assessed by clinical examination |
Not provided
Inclusion Criteria:
3a. Subject will be undergoing an elective laparoscopy with a planned possibility of a conversion to midline laparotomy or an elective laparoscopy with a planned possible midline laparotomy for specimen extraction.
Pre-Operative Exclusion Criteria:
Subject is undergoing emergency surgery, i.e. lifesaving procedures performed where patient is in imminent danger of death
Subject has a history of allergic reactions after application of poly-L-lactide, poly-trimethylene carbonate copolymers (PLLA/TMC)
Subject is pregnant or is planning pregnancy during study duration period (Females of child-bearing potential will be required to provide either a urine or serum pregnancy test (except for subjects who are surgically sterile or are at least 2 years postmenopausal)) 3a. Subject is breastfeeding or is planning to breastfeed during the study duration period
Subject is unable or unwilling to comply with the study requirements or follow-up schedule
Subject is scheduled for another planned surgery, and subsequent surgery would jeopardize previous application of study treatment
Subject with a body mass index (BMI) > 45 kg/m2
Subjects with the following medical interventions/medical conditions are excluded from participation in the study: uncontrolled diabetes (hemoglobin A1c (Hb1Ac) > 60mmol/mol), cirrhosis, stoma wearers
Concomitant ostomy (stoma creation or closure)
Subject who had received a mesh in a previous ventral hernia repair or has an existing ventral hernia > 2 cm
Subject with a life expectancy inferior to the study follow-up duration (36 months)
Study procedure is a relaparotomy within 30 days of previous abdominal surgery
Subject with an American Society of Anesthesiologists (ASA) scores higher than 3
Subject has participated in an investigational drug study within the washout period of the drug or in a device study that would interfere with mesh implantation or assessment of Incisional Hernia
Subject with current chemo and/or radiation therapy within 2 weeks of procedure
Only exclusion of chemotherapeutic drugs that have:
Subject with any history of ascites
Subject has a medical condition that precludes the patient from participation in the opinion of the investigator
Subject is undergoing a vascular procedure other than abdominal aortic aneurysm (AAA) surgery (i.e, only AAA surgeries accepted)
Intraoperative Exclusion criteria
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Name | Affiliation | Role |
|---|---|---|
| Elisa Mäkäräinen, MD | Oululu University Hospital, Oululu, Finland | Study Chair |
| Facility | Status | City | State | ZIP | Country | Contacts |
|---|---|---|---|---|---|---|
| Clinical Hospital Center Sisters of Mercy | Zagreb | 10000 | Croatia | |||
| University Hospital Center of Zagreb |
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| 3-, 6-, 12-, 24-, and 36- months |
| Time to Incisional Hernia | Time from surgery to incisional hernia | From the surgery to the 60-month visit |
| Time to other adverse device effects (ADE) | Time from skin incision to ADE | From the surgery to the 60-month visit |
| Incidence of all adverse device effects (ADEs) | Adverse device effects related to mesh and mesh-augmented reinforcement procedure | Intra-operatively, at discharge (post-surgery up to 3-mo), and within 3-, 6-, 12-, 24-, 36-, 48- and 60- months |
| Incidence of adverse events (AEs) of interest | AEs of interest: symptomatic seroma requiring action taken, hematoma needing surgical revision, surgical site infection (SSI) defined via the CDC classification of SSI (superficial, deep or organ space), wound dehiscence (skin and/or fascial), mesh removal | Intra-operatively, at discharge (post-surgery up to 3-mo), and within 3-, 6-, 12-, 24-, 36-, 48- and 60- months |
| Pain at the site of surgery evaluated with Numeric Rating Scale (NRS) | Scale from 0-10, with 0 being no pain and 10 being the worst imaginable pain | baseline (screening), discharge (post-surgery up to 3-mo) and at 3-, 6-, 12-, 24-, and 36- months |
| EQ-5D-5L quality of life (QoL) | Self-administered QOL questionnaire with 5 questions on quality of life and a numeric scale from 0-100 with 0 being the worst health you can imagine and 100 being the best health you can imagine. | Baseline and at 3-, 6-, 12-, 24-, and 36- months |
| Surgeon Satisfaction | Surgeon satisfaction questionnaire on mesh use | Day 0, post-operative |
| Hospital length of stay | Amount of time spent inpatient | Hospital admission to hospital discharge (post-surgery up to 3-mo) |
| Readmission and reoperation rate | Related to Mesh device and/or Mesh Augmented Reinforcement procedure. | From the surgery to the 60-month visit |
| Incisional Hernia Rate | Occurrence of incisional hernia when suspected during phone call follow-up visits and subsequently assessed by clinical examination and abdominal ultrasound exam | 48- and 60-months |
| Incisional Hernia Rate | Occurrence of incisional hernia when suspected during phone call follow-up visits and subsequently assessed by clinical examination | 48- and 60-months |
| Incisional Hernia Rate | Occurrence of incisional hernia reported by subjects through the "modified " PROMID questionnaire administered at phone call follow-up visits | 48- and 60-months |
| Zagreb |
| 10000 |
| Croatia |
| Klinikum Braunschweig | Braunschweig | 38118 | Germany |
| Pius-Hospital Medical Campus University of Oldenburg | Oldenburg | 26121 | Germany |
| Barmherzige Brüder Regensburg | Regensburg | 93049 | Germany |
| IJsselland Ziekenhuis | Capelle aan den IJssel | Netherlands |
| Maastricht University Medical Center | Maastricht | 6229 | Netherlands |
| Consorci Sanitari de l'Anoia Hospital Universitari d'Igualada | Igualada | Barcelona | 08700 | Spain |
| Hospital de la Santa Creu i Sant Pau | Barcelona | 08041 | Spain |
| Hospital Universitario Ramón y Cajal | Madrid | 28034 | Spain |
| Hospital Universitario Virgen Macarena | Seville | 41009 | Spain |
| Countess Of Chester Hospital NHS Foundation Trust | Chester | Cheshire | CH2 1HJ | United Kingdom |
| Cardiff and Vale University Local Health Board | Cardiff | CF14 4XW | United Kingdom |
| ID | Term |
|---|---|
| D000069290 | Incisional Hernia |
| ID | Term |
|---|---|
| D006547 | Hernia |
| D020763 | Pathological Conditions, Anatomical |
| D013568 | Pathological Conditions, Signs and Symptoms |
| D011183 | Postoperative Complications |
| D010335 | Pathologic Processes |
Not provided
Not provided